Literature DB >> 17852415

Human endometrium mRNA profile assessed by oligonucleotide three-dimensional microarray.

Audrey Y Otsuka1, Priscila M Andrade, Fabiola E Villanova, Ricardo C Borra, Ismael D C G Silva.   

Abstract

Our purpose, in the present work, was to further comprehend the genetic events underlying the response to steroids of human endometrium from the mRNA as well as protein expression point of view. In order to achieve this goal we undertook 10,000-oligonucleotide, three-dimensional microarray analysis, followed by immunohistochemistry, on human normal endometrium in the proliferative and secretory phases of the menstrual cycle. The results revealed that a myriad of genes involved in immune response, calcium metabolism and thyroid hormone response were frequently overexpressed in the second or luteal phase of the menstrual cycle. During the follicular phase, in contrast, overexpression of genes was mainly restricted to those encoding proteins involved in cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17852415     DOI: 10.1080/09513590701550221

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  2 in total

1.  Analysis of differentially expressed genes in colorectal adenocarcinoma with versus without metastasis by three-dimensional oligonucleotide microarray.

Authors:  Rita M A M Moura Franco; Marcelo M Linhares; Suzana S Lustosa; Ismael D G C Silva; Naiara C N Souza; Delcio Matos
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

2.  Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers.

Authors:  Signe Altmäe; Mariann Koel; Urmo Võsa; Priit Adler; Marina Suhorutšenko; Triin Laisk-Podar; Viktorija Kukushkina; Merli Saare; Agne Velthut-Meikas; Kaarel Krjutškov; Lusine Aghajanova; Parameswaran G Lalitkumar; Kristina Gemzell-Danielsson; Linda Giudice; Carlos Simón; Andres Salumets
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.